simplyStocks
Edwards Lifesciences
EW · NYSEMedical Devices
The economic chain
Follow the chain left → right, from inputs to end demand. Tap any company to trace its links.
Raw inputs
Equipment
Foundry
Chip design
Software
AI demand
—
Company details
Market cap
~$48B
P/E ratio
~36×
Div yield
0%
Revenue
~$6.1B
Rev. growth
+11.5%
R&D / sales
~18%
Free cash flow
~$1.3B
Net cash
~$2.4B
In plain English
Edwards Lifesciences is the world leader in fixing diseased heart valves without open-chest surgery. Its SAPIEN transcatheter aortic valves — bovine tissue mounted in a metal frame, threaded up through an artery — are the gold standard, and it is now extending that catheter playbook to the mitral and tricuspid valves. After selling its Critical Care monitoring arm to BD in 2024, it is a pure-play structural-heart company.
In simple terms
What Edwards Lifesciences really sells
Edwards Lifesciences is the world leader in fixing diseased heart valves without open-chest surgery. Its SAPIEN transcatheter aortic valves — bovine tissue mounted in a metal frame, threaded up through an artery — are the gold standard, and it is now extending that catheter playbook to the mitral and tricuspid valves. After selling its Critical Care monitoring arm to BD in 2024, it is a pure-play structural-heart company.
Tip · Click any company in the map to learn — in one sentence — what it actually does and why it matters.
Risk read
SteadierMore speculative
Why this rating?